Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message? - Chan EC, Vernon SW, O'Donnell FT, Ahn C, Greisinger A, Aga DW, Division of General Internal Medicine, University of Texas-Houston Medical School, Houston, TX. Am J Public Health 2003;93:779-785

Author： Carroll P.R.  

Publisher： Elsevier

ISSN： 1078-1439

Source： Urologic Oncology: Seminars and Original Investigations, Vol.21, Iss.6, 2003-11, pp. : 484-484

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer - Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA, Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI. J Natl Cancer Inst 2003;95:661-668

By Chatta G.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 488-488

Elsevier

Access to resources Recommend Favorite

Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer. Li M, Ittmann MM, Rowley DR, Knowlton AA, Vaid AK, Epner DE, Departments of Medicine, Pathology, Molceular and Cellular Biology, Baylor College of Medicine and VA Medical Center Houston, TX 77030 - Prostate 2003;56(2):98-105

By Bosland M.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 415-416

Elsevier

Access to resources Recommend Favorite

Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ, Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX - Cancer 2003;97:561-567

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 412-412

Elsevier

Access to resources Recommend Favorite

Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor - Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH, Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY. J Nucl Med 2003;44:610-617

By Carroll P.R.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 486-487

Elsevier

Access to resources Recommend Favorite

Factors influencing primary care physicians’ decision to order prostate-specific antigen (PSA) test for men without prostate cancer

By Hayat Roshanai Afsaneh   Nordin Karin   Berglund Gunilla  

Acta Oncologica, Vol. 52, Iss. 8, 2013-11 ,pp. : 1602-1608

Informa Healthcare

Access to resources Recommend Favorite